Skip to content
Company Analysis

Astrazeneca PLC AZN

A comprehensive view of key metrics, scores, and financial health for Astrazeneca PLC

Overview of AstraZeneca PLC

AZN NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mega Cap
AstraZeneca PLC (AZN), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $186.58, about 53.7% overvalued vs fair value, +10.4% 1Y return, ranked 793/1145 in sector.
Metrics P/E 26.8× Rev Growth 8.6% ROE 22.9% Gross Margin 81.9% Div Yield 1.74%
USD 186.58
-0.04%
(Delayed)
• Vol 90d: 33.5%
52-Week Range
Market Cap
$289.39B
Enterprise Value
$314.06B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Completeness: 100%
Confidence: 97%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.astrazeneca.com
HQ Cambridge
Employees 96,100
Fiscal year Dec 31

Next Events

Earnings Oct 30 Call: Oct 30

Fair Value Snapshot

Bear Base Bull
$79
$86
$94
Current: $186.58 -54% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$58.7B
8.6%%
Gross Profit
$48.1B
9.7%%
R&D Expense
$14.2B
4.8%%
Operating Income (EBIT)
$14.0B
35.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
104.0%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.7B
65.6% of FCF

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Astrazeneca PLC's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
53
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 1.00), with margins expanding over time.

Key risks

  • Below-Peer Operating Efficiency Operating margin at 38.9th percentile indicates below-peer efficiency.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.28), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
52
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 97% Coverage
Trade-Off Triangle Visualization A ternary plot showing AZN's balance between Growth (34.8%), Profitability (43.1%), and Safety (22.2%). Growth 35% Safety 22% Profitability 43%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

66th percentile vs peers
67
Key Signals
Rev Growth YoY 8.6% 64p Revenue CAGR 3Y 9.8% 64p EPS CAGR 3Y 45.9% 91p EPS Growth YoY 45.4% 50p TSR 37.5% 73p
Strengths
  • EPS CAGR 3Y in top 20% of peers (45.9%, 91th percentile)
  • Interest Coverage Ratio in top 20% of peers (8.68, 83th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

82th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

42th percentile vs peers
43
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Astrazeneca PLC.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$86.41
- - -
-53.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000